Weight Loss Jabs Trigger Rapid Weight Regain, Study Finds

Published: 08 January 2026. The English Chronicle Desk. The English Chronicle Online.

A new study reveals people stopping weight loss jabs often regain lost weight rapidly, challenging perceptions. Researchers from the University of Oxford examined 37 studies covering 9,341 participants, highlighting that those who discontinued weight loss jabs regained their original weight within under two years. The weight loss jabs, medically known as GLP-1 agonists, mimic the hormone glucagon-like peptide 1, which naturally signals fullness and helps manage appetite. During treatment, participants lost an average of 8.3kg, yet within the first year after stopping, nearly 4.8kg returned, showing how weight loss jabs provide temporary results without long-term lifestyle support.

The analysis found weight was regained at approximately 0.4kg per month after discontinuing treatment, meaning most participants returned to their original weight in roughly 1.7 years. This pattern occurred significantly faster than for individuals using behavioral weight loss programs, which often include structured diets or exercise routines. Experts emphasize that this rapid regain does not reflect failure of the medications themselves, but rather the chronic nature of obesity, which requires ongoing management beyond short-term interventions.

Dr Sam West, of Oxford’s Nuffield Department of Primary Care Health Sciences, explained the findings underscore the importance of comprehensive weight management strategies. “These medicines are transforming obesity treatment and can achieve important weight loss,” Dr West said. “However, our research shows people regain weight rapidly after stopping – faster than with behavioral programs. This isn’t a failing of the medicines, but highlights the chronic, relapsing nature of obesity.”

Weight loss jabs, which include drugs such as Wegovy and Mounjaro, are available via NHS prescriptions, with Wegovy limited to two years of use and no specific time limit for Mounjaro. While effective in helping people lose weight and reduce type 2 diabetes risk, the study highlights that long-term success relies on continued lifestyle support and preventive measures. Participants in the research not only regained weight but also returned to baseline levels for cardio-metabolic health markers, including blood pressure and cholesterol, within approximately 1.4 years after discontinuing medication.

Dr Faye Riley, research communications lead at Diabetes UK, emphasized that these drugs should be considered tools within a broader strategy rather than standalone solutions. “They need to be prescribed appropriately, with tailored wraparound support, to help individuals maintain weight loss after stopping the medication,” Dr Riley said. This advice is echoed by Katharine Jenner, executive director of the Obesity Health Alliance, who noted that the food environment itself often undermines sustained success.

“The reality of living in a food environment promoting unhealthy options makes long-term maintenance challenging,” Jenner said. “Weight loss jabs can provide a window to improve dietary habits and healthier food access, but without systemic changes, benefits may not persist.” NHS officials also emphasized that medication must be complemented by behavioral guidance and lifestyle interventions, such as the NHS digital weight management program, which will expand to reach 125,000 additional participants annually.

The Oxford-led study provides precise timelines for weight regain, a first in obesity research, offering critical insights for patients and clinicians. While previous evidence suggested weight return within a year, this research quantifies both the rate and duration, enabling healthcare providers to plan structured interventions around treatment cessation. The findings reinforce the importance of viewing weight loss jabs as part of a holistic approach to obesity management rather than a quick fix.

Healthcare experts recommend integrating weight loss jabs with behavioral programs, dietary support, and physical activity. By combining medication with sustainable lifestyle changes, patients may extend health benefits, preserve weight loss, and reduce cardio-metabolic risks. Dr West stressed that obesity is a chronic condition requiring ongoing attention and comprehensive management strategies beyond the temporary effects of medication.

As demand for effective obesity treatments increases, the study encourages policymakers, clinicians, and public health organizations to create environments that support lasting healthy habits. While weight loss jabs offer promising results, the rapid regain observed underlines the limitations of relying solely on pharmacological interventions. Ensuring patients receive structured guidance and systemic support is key to achieving enduring outcomes in weight and overall health management.

Check our latest news